AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04968158
Drug: Etoricoxib 90 mg / Tramadol 50 mg
DrugBank: Tramadol (DB00193)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One packet diluted in 100 ml of water, every 24 hours of 90 mg/50 mg.
Trial: NCT05975749
Drug: Serplulimab
RxNorm normalized name: Serplulimab
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Serplulimab: 4.5mg/Kg on day 1
Trial: NCT05975749
Drug: Trastuzuma
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Trastuzuma: 8mg/Kg ( the first cycle)，6mg/Kg (the rest of cycles) on day 1
Trial: NCT03643198
Drug: ANTIBIOTIC (METRONIDAZOLE AND CIPROFLOXACIN)
RxNorm normalized name: metronidazole and diloxanide
DrugBank: Gramicidin D (DB00027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The control group will receive two types of placebo tablets that look identical to Ciprofloxacin and Metronidazole respectively, with similar doses and frequencies.
Trial: NCT05599256
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Model-predicted high-risk patients: weight ≤ 25 kg, ruxolitinib, 2.5mg bid po until at least day 60 post-transplant and terminated after day 100; weight \> 25 kg, ruxolitinib, 5mg bid po until at least day 60 post-transplant and terminated after day 100. If 'azoles' are taken concomitantly, ruxolitinib will start at half dose. If the patient tolerates ruxolitinib, the dose can be increased to 10mg bid po.~Model-predicted low risk: regular aGVHD prophylactic regimens.
Trial: NCT05650268
Drug: Vitamin D3
RxNorm normalized name: Vitamin D3
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Receiving 576000 international units in single oral dose of liquid vitamin D 3\~7 days prior to the surgery.
Trial: NCT06247085
Drug: Pegtibatinase
RxNorm normalized name: Pegtibatinase
DrugBank: Pegtibatinase (DB17677)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full Target Dose of pegtibatinase BIW
Trial: NCT04703088
Drug: Ondansetron 4 MG
RxNorm normalized name: ondansetron 4 MG
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mL of a solution of Ondansetron containing 2mg/ml in a 3 ml syringe will be given intravenously to a patient five minutes before positioning for induction of spinal anesthesia
Trial: NCT06012682
Drug: Metformin Hydrochloride
RxNorm normalized name: Metformin Hydrochloride
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: The investigational medicinal product/placebo will be dispensed to study participants by study staff during randomization visits V1, V2, V3, V4, V5 and V6.~The randomized patient will receive the investigational medicinal product/placebo in tablets of 500 mg. The received tablets will be dispensed in an amount sufficient for the next visit. Patients will be asked to bring unused medicine and all empty ones packaging to the Center for each subsequent visit. The investigational medicinal product/placebo will be administered orally 500 mg three times a day (Table No. 1). The dose of the study product will be gradually increased from 500 mg/day to 1500 mg/day in order to avoid or reduce side effects related to taking the study medicinal product metformin
Trial: NCT05255523
Drug: pyrotinib
RxNorm normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After 4-6 cycles of taxane chemotherapeutics combined with trastuzumab±pertuzumab, the assessment result reaches CR or PR, and the subsequent sequential pyrrotinib plus capecitabine±trastuzumab to CNS Progress
Trial: NCT04891458
Drug: Patients received lighter sedation with propofol after spinal anesthesia.
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MOAA/S 0-2.
Trial: NCT04891458
Drug: Patients received heavier sedation with propofol after spinal anesthesia
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: MOAA/S 3-5.
Trial: NCT04891458
Drug: Patients received lighter sedation with dexmedetomidine after spinal anesthesia
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MOAA/S 0-2.
Trial: NCT04891458
Drug: Patients received heavier sedation with dexmedetomidine after spinal anesthesia.
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MOAA/S 3-5.
Trial: NCT05057481
Drug: Mycophenolate Mofetil 500mg
RxNorm normalized name: MYCOPHENOLATE MOFETIL 500MG TAB
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: MMF 2gram/day orally for 12 weeks
Trial: NCT05057481
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 375 mg/m2 of rituximab given intravenously weekly for 4 weeks.
Trial: NCT01132794
Drug: Intranasal dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1mcg per kg dexmedetomidine given intranasally 45 minutes before operation
Trial: NCT03624842
Drug: Trappsol (R) Cyclo (TM)
RxNorm normalized name: pantolactone, (R)-
DrugBank: Cyclo(his-pro) (DB02414)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04877834
Drug: Dexlansoprazole
RxNorm normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole capsule prepared by SAMI Pharmaceuticals will be administered to this arm.
Trial: NCT04877834
Drug: Dexlansoprazole
RxNorm normalized name: Dexlansoprazole
DrugBank: Dexlansoprazole (DB05351)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dexlansoprazole capsule prepared by Takeda Pharmaceutical Company will be administered to this arm.
Trial: NCT06367335
Drug: Ribociclib, palbociclib, abemaciclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: evaluate the presence of predictors useful to predict the development of DILI during treatment with CKI
Trial: NCT05055024
Drug: Mazindol
RxNorm normalized name: Mazindol
DrugBank: Mazindol (DB00579)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: NLS-2
Trial: NCT06155422
Drug: Cadonilimab
RxNorm normalized name: Cadonilimab
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: recurrent or metastatic cervical cancer in the first, second or third lines Systematic treatment
Trial: NCT00001118
Drug: Enfuvirtide
RxNorm normalized name: Enfuvirtide
DrugBank: Enfuvirtide (DB00109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05430958
Drug: INO-4800
RxNorm normalized name: INO-4800
DrugBank: INO-4800 (DB15693)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: INO-4800 will be given at 0.8 or 1.6 mg for at least 6 months but no more than 12 months following the completion of a primary vaccination.
Trial: NCT05996588
Drug: Propofol 1 % Injectable Suspension
RxNorm normalized name: propofol 1 % Injectable Suspension
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol 1 % Injectable Suspension at a rate of 50 microgram/kg/min intravenously
Trial: NCT05996588
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sevoflurane inhalation anaesthetic at a concentration of 4-5% to achieve a MAC of 0.25
Trial: NCT05430958
Drug: INO-9112
RxNorm normalized name: INO
DrugBank: Inosine (DB04335)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: INO-9112 will be given in at various doses (dose of 0, 0.05, 0.10, 0.20 or 0.40 mg) in combination with INO-4800.
Trial: NCT05404906
Drug: Azacitidine
RxNorm normalized name: Azacitidine
DrugBank: Azacitidine (DB00928)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given SC
Trial: NCT05404906
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT05210413
Drug: Spartalizumab in Pediatric cohort
RxNorm normalized name: Spartalizumab
DrugBank: Spartalizumab (DB14892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of spartalizumab at four dose escalation levels: 2, 3, 4 and 6 mg/kg in successive cohorts of 3 patients, depending on the number of patients with dose-limiting toxicity (DLT) to maximum tolerated dose (MTD).
Trial: NCT05210413
Drug: Low-dose Pazopanib in Pediatric Cohort
RxNorm normalized name: ethinyl estradiol
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral pazopanib treatment at a fixed dose of 225mg/m²/day
Trial: NCT05210413
Drug: Spartalizumab in Adult cohort
RxNorm normalized name: OC 8 Adult Acne
DrugBank: Spartalizumab (DB14892)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 400 mg of spartalizumab on Day1 of each cycle.
Trial: NCT05210413
Drug: Low-dose Pazopanib in Adult Cohort
DrugBank: Pazopanib (DB06589)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral pazopanib treatment with a fixed dose of 400 mg/day
Trial: NCT04874935
Drug: Lansoprazole
RxNorm normalized name: Lansoprazole
DrugBank: Lansoprazole (DB00448)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: administration of lansoprazole 60 mg twice daily 4 days before starting neoadjuvant chemotherapy regimen and continue till end of chemotherapy cycles
Trial: NCT05301517
Drug: SEPO®
RxNorm normalized name: Selegiline
DrugBank: Selegiline (DB01037)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SEPO® will be administered per dose and schedule specified in the arm description.
Trial: NCT05301517
Drug: Roxadustat
RxNorm normalized name: roxadustat
DrugBank: Roxadustat (DB04847)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Roxadustat will be administered per dose and schedule specified in the arm description.
Trial: NCT05283395
Drug: Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution
DrugBank: Latanoprost (DB00654)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Commercially available ophthalmic solution indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension
Trial: NCT05054140
Drug: IMU-838
RxNorm normalized name: LACTOBACILLUS HELVETICUS 1.50 g in 150 mL / RICE BRAN 1.50 g in 150 mL TOPICAL AEROSOL, FOAM [IMU]
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IMU-838 tablets
Trial: NCT05939076
Drug: dronedarone - Multaq™ OR flecainide - Tambocor™ OR propafenone - Rytmonorm™ OR sotalol - Sotacor™
DrugBank: Sotalol (DB00489)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drugs
Trial: NCT05939700
Drug: Mavacamten
RxNorm normalized name: Mavacamten
DrugBank: Mavacamten (DB14921)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Observational study of individuals exposed to at least 1 dose of mavacamten at any time during pregnancy and/or breastfeeding
Trial: NCT05813860
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 5mg/kg for the first dose, and the same dose at weeks 2 and 6 after the first dose and every 8 weeks thereafter. Treatment with single Infliximab or combined azathioprine, respectively.
Trial: NCT05909462
Drug: 2 ml of 40 mg triamcinolone acetonide and 4 ml of 1% lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ultrasonography-guided suprascapular nerve block and intra-articular shoulder injection
Trial: NCT04921566
Drug: Torasemide tablet 10 mg
RxNorm normalized name: torasemide
DrugBank: Torasemide (DB00214)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Torasemide is manufactured by Pharmtechnology LLC, Belarus. Each tablet contains 10 mg of torasemide.
Trial: NCT05697783
Drug: Administration of methadone instead of fentanyl patch
RxNorm normalized name: OIL OF CAMPHOR
DrugBank: Methadone (DB00333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: comparison of delirium rates in methadone vs fentanyl patch treated patients
Trial: NCT04873895
Drug: Axitinib 5 MG
RxNorm normalized name: axitinib 5 MG
DrugBank: Axitinib (DB06626)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: axitinib 5 mg po BID until progression or intolerance
Trial: NCT04873895
Drug: Hydroxychloroquine Pill
RxNorm normalized name: hydroxychloroquine Pill
DrugBank: Chloroquine (DB00608)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hydroxychloroquine 600 mg po BID until progression or intolerance
Trial: NCT05190419
Drug: Orismilast modified release tablets
DrugBank: Orismilast (DB19042)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Orismilast modified release is a next generation phosphodiesterase-4 (PDE4) inhibitor with high selectivity for the PDE4 subtypes linked to inflammation.
Trial: NCT06258031
Drug: Psilocybin (COMP360)
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Up to 10mg on two occasions
Trial: NCT06023186
Drug: mavacamten
RxNorm normalized name: Mavacamten
DrugBank: Mavacamten (DB14921)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study participants will receive mavacamten under the standard of care
Trial: NCT06014827
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given PO
Trial: NCT04191434
Drug: Flamboyant 125/12
DrugBank: Lamb (DB10537)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flamboyant 125/12 capsule
Trial: NCT04191434
Drug: Budesonide/formoterol 200/6
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonid/formoterol 200/6 capsule
Trial: NCT05510245
Drug: PF-07081532
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One PF-07081532 20 mg tablet, administered orally
Trial: NCT05087771
Drug: injectable naltrexone
RxNorm normalized name: naltrexone Injection
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 360 mg dose to be given prior to hospital discharge
Trial: NCT05087771
Drug: oral naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg tab dispense 30 day supply to be given at hospital discharge
Trial: NCT06394570
Drug: Enfortumab vedotin
RxNorm normalized name: ENFORTUMAB VEDOTIN
DrugBank: Enfortumab vedotin (DB13007)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enfortumab Vedotin administered 1.25mg/kg (max 125mg) IV on Day 1 and Day 8 of each 21 day cycle x 3 cycles
Trial: NCT03816228
Drug: F 18 T807 Flortaucipir
RxNorm normalized name: Flortaucipir F-18
DrugBank: Flortaucipir (DB15033)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
Trial: NCT05447260
Drug: Ruxolitinib
RxNorm normalized name: Ruxolitinib
DrugBank: Ruxolitinib (DB08877)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dosage based on platelet count
Trial: NCT05686434
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: This is a prospective, open, single-center, single-arm phase II clinical study with EGFR-sensitive mutations (Ex19del and L858R) identified in the central laboratory，to evaluate the efficacy and safety of adjuvant Osimertinib therapy in completely resected stage I non-squamous non-small cell lung cancer (NSCLC) with high-risk factors (solid and/or micropapillary component ≥10%, and/or airway spread).
Trial: NCT06210334
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tislelizumab 200mg, iv, d3, q3w
Trial: NCT06210334
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenvatinib 8mg (\<60kg) or 12mg (≥60kg), po, qd
Trial: NCT05265104
Drug: SDF with stainless steel crown
RxNorm normalized name: Primatene with ephedrine Pill
DrugBank: Ephedrine (DB01364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Silver Diamine Fluoride (38%) applied to the carious lesion in the primary molars with a brush and the tooth is sealed with a stainless steel crown
Trial: NCT02528708
Drug: fibrinogen concentrate
RxNorm normalized name: Fibrinogen concentrate human
DrugBank: Fibrinogen human (DB09222)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The dose of fibrinogen concentrate needed to achieve this target will be calculated using a formula that accounts for the baseline FIBTEM® - A10 value and the patient's body weight assessed at hospital admission . In general, a 70-kg patient requires a fibrinogen dose of approximately 0.5 g to increase the MCF by approximately 1 mm.
Trial: NCT05510063
Drug: Humira (Adalimumab)
RxNorm normalized name: adalimumab Prefilled Syringe [Humira]
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous (SC) injection
Trial: NCT05510063
Drug: SB5 (Adalimumab Biosimilar)
RxNorm normalized name: SB5+
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subcutaneous (SC) injection
Trial: NCT05626101
Drug: BCG
RxNorm normalized name: BCG
DrugBank: Bacillus calmette-guerin substrain danish 1331 live antigen (DB12386)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravsical induction and maintenance BCG injections.
Trial: NCT05626101
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravsical induction and maintenance gemcitabin injections.
Trial: NCT05117736
Drug: Sacubitril / Valsartan Oral Tablet
RxNorm normalized name: sacubitril / valsartan Oral Tablet
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: For the first phase of the trial, each patient will be randomized to active therapy (50, 100, or 200 mg bid of Sacubitril/Valsartan based on the run-in phase) or the corresponding placebo (matching tablets for the 50,100 or 200mg of Sacubitril/Valsartan), with the sequence reversed in the second phase.
Trial: NCT05574296
Drug: Hydrogen
RxNorm normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogen gas (2%) in air or oxygen administered for 72 hours via ventilator and ECMO membrane. Oxygen concentration titrated per clinical team.
Trial: NCT04781881
Drug: Entresto
RxNorm normalized name: Entresto
DrugBank: Valsartan (DB00177)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: There is no treatment allocation. Patients administered Entresto by prescription that have started before inclusion of the patient into the study will be enrolled.
Trial: NCT04830501
Drug: TT-00434
RxNorm normalized name: TT 173
DrugBank: TT 173 (DB17717)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once daily \[QD\], 28 days/cycle.
Trial: NCT05094050
Drug: ABBV-951
RxNorm normalized name: ABBV-514
DrugBank: ABBV-514 (DB17586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous Subcutaneous Infusion (CSCI)
Trial: NCT04920617
Drug: DPX-Survivac
RxNorm normalized name: DPX-Survivac
DrugBank: Maveropepimut-S (DB17339)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SC injection on D7 and D28, then every 8 weeks
Trial: NCT04920617
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion every 3 weeks
Trial: NCT06241235
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV infusion
Trial: NCT06241235
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT06241235
Drug: Carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: IV infusion
Trial: NCT04136808
Drug: enfortumab vedotin (EV)
DrugBank: Enfortumab vedotin (DB13007)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive an intravenously (IV) administered dose once weekly for the first 3 weeks of every 4-week cycle (i.e., on days 1, 8, and 15)
Trial: NCT05116683
Drug: ATX-101
RxNorm normalized name: ATX-101
DrugBank: ATX-101 (DB05780)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given ATX-101 at 60 mg/m2 IV weekly in continuous 21 day cycles.
Trial: NCT04969029
Drug: Tirelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In the immunotherapy group, the treatment regimen was Tirelizumab 200mg, intravenously infused once every 3 weeks until the end of 12 months of treatment, with a total of 17 infused times.
Trial: NCT06256588
Drug: Dostarlimab
RxNorm normalized name: Dostarlimab
DrugBank: Dostarlimab (DB15627)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Dostarlimab will be administered as an intravenous (IV) infusion
Trial: NCT04508166
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Volunteers receive a single dose of dexmedetomidine sublingually at scheduled bedrest in the sleep laboratory
Trial: NCT04508166
Drug: Gamma-Hydroxybutyrate
RxNorm normalized name: gamma-Hydroxybutyrate
DrugBank: gamma-Hydroxybutyric acid (DB01440)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Volunteers receive a single oral dose of gamma-hydroxybutyrate at scheduled bedrest in the sleep laboratory
Trial: NCT05543954
Drug: 68Ga-FAPI-RGD
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 68Ga-FAPI-RGD with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.
Trial: NCT05543954
Drug: 18F-FDG
RxNorm normalized name: 18F-FDG
DrugBank: Fludeoxyglucose (18F) (DB09502)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 18F-FDG with a dosage of approximately 3.7-5.55 MBq (0.1-0.15 mCi)/kg.
Trial: NCT05543954
Drug: 68Ga-FAPI
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 68Ga-FAPI with a dosage of approximately 1.8-2.2 MBq (0.05-0.06 mCi)/kg.